[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412373":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":38,"centralContacts":37,"locations":41,"responsibleParty":64,"collaborators":37,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":37,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":37,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":92,"whyStopped":93,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,15,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Dose 1 or placebo","EXPERIMENTAL","Chinese participants",[13,14],"Biological: BMS-986036","Other: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 2: Dose 2 or placebo",[13,14],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3: Dose 1 or placebo","Korean participants",[13,14],{"label":23,"type":10,"description":20,"interventionNames":24},"Cohort 4: Dose 2 or placebo",[13,14],[26,33],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"BIOLOGICAL","BMS-986036","Specified dose on specified days",[9,16,19,23],[32],"Pegbelfermin",{"type":34,"name":35,"description":29,"armGroupLabels":36,"otherNames":37},"OTHER","Placebo",[9,16,19,23],null,[39],{"name":5,"affiliation":5,"role":40},"STUDY_DIRECTOR",[42,55],{"facility":43,"status":37,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":37},"Local Institution","Changchun","Jilin","130021","China","CN",{"type":50,"coordinates":51},"Point",[52,53],125.32278,43.88,{"lat":53,"lon":52},{"facility":43,"status":37,"city":56,"state":37,"zip":57,"country":58,"countryCode":37,"cosmosGeoPoint":59,"geoPoint":63,"contacts":37},"Busan","614-735","South Korea",{"type":50,"coordinates":60},[61,62],129.03004,35.10168,{"lat":62,"lon":61},{"type":65,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100412373","phase-1-a-study-to-evaluate-the-drug-levels-and-safety-of-pegbelfermin-in-healthy-overweight-and-obese-chinese-and-korean-participants-100412373",false,"NCT04649710","A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants","A Double-Blind, Multicenter, Placebo-Controlled, Randomized, Parallel, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants","Inclusion Criteria:\n\n* Overweight and obese, but otherwise healthy Chinese and Korean participants, as determined by no clinically significant deviations from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations\n* Additional criterion for Chinese participants: must be first generation Chinese (born in China and not living outside of China for \\> 10 years, and both parents are ethnically Chinese)\n* Additional criterion for Korean participants: must be first generation Korean (born in Korea and not living outside of Korea for \\> 10 years, and both parents are ethnically Korean)\n* Must agree to follow specific methods of contraception, if applicable\n\nExclusion Criteria:\n\n* BMI ≥ 40 kg\u002Fm\\^2\n* Women who are pregnant or breastfeeding\n* History of allergy to pegylated compounds or fibroblast growth factor 21-related compounds\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply",true,"ALL","18 Years","65 Years",{"count":78,"type":79},0,"ACTUAL","INTERVENTIONAL",[82],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, and drug level of Pegbelfermin in healthy overweight and obese Chinese and Korean participants.",[85],"Healthy Participants",[87,88,89,90,91,32],"Chinese","Ethnicity","Korean","Obese","Overweight","WITHDRAWN","Business objectives have changed","2022-04-25",{"date":96,"type":79},"2022-04-28",{"date":98,"type":99},"2021-06-21","ESTIMATED",{"date":101,"type":99},"2021-09-22",{"name":5,"class":6},2]